Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma | NEJM
Bortezomib, thalidomide and dexamethasone protocol (VTD). | Download Scientific Diagram
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study - ScienceDirect
Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma | Haematologica
British Journal of Haematology | Wiley Online Library
VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma | 2 Minute Medicine
Phase I/II Trial of Panobinostat with Lenalidomide/Bortezomib/ Dexamethasone for Transplant-Eligible Patients with Newly Diagnosed MM | Research To Practice
A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD - CDCN
Adding daratumumab to bortezomib-dexamethasone improves survival in myeloma patients - BJH
DREAMM Clinical Trial Program
British Journal of Haematology | Wiley Online Library
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial - The Lancet
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Treatment of Relapsed/Refractory Multiple Myeloma with Bendamustine, Bortezomib and Dexamethasone | Research To Practice
VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma | 2 Minute Medicine
The Lancet on X: "NEW—First large randomised phase 3 trial (BOSTON) finds regimen of selinexor, bortezomib & dexamethasone was associated with significant increase in progression-free survival vs bortezomib & dexamethasone in patients
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma | Published in Journal of Health Economics and Outcomes Research
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
